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Purpose: Cardiovascular and metabolic adverse events are costly to treat, and their inci-
dence is increased amongst people with schizophrenia, with different rates observed for 
second-generation antipsychotics. To inform treatment choice, this study sought to estimate 
the lifetime costs associated with antipsychotic choice, and how these costs varied across 
European countries.
Methods: Systematic searches were conducted to identify evidence on effectiveness and 
costs. A Markov model was developed to assess the costs of ten antipsychotics: aripiprazole, 
brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, 
risperidone and ziprasidone. Costs were obtained for seven countries: Italy, Hungary, France, 
Slovenia, Spain, Sweden and the UK. The costs considered were adverse events (including 
diabetes, myocardial infarction, stroke and weight gain), drug costs, relapse, treatment 
discontinuation and schizophrenia management. Two adult populations were modelled; 
initiating either acute or maintenance treatment, with a lifetime horizon for both.
Results: Lurasidone was associated with the lowest lifetime costs amongst patients initiating 
acute treatment compared to all other atypical antipsychotics considered. The second lowest 
costs were for ziprasidone. These results were observed for all seven countries. The main 
drivers of cost differences were rates of diabetes and cardiovascular diseases, which were 
lowest for lurasidone, followed by ziprasidone then lumateperone. Costs for managing 
weight gain were lowest for lurasidone and ziprasidone. Similar results were observed for 
patients initiating maintenance treatment.
Conclusion: Diabetes and cardiovascular events are large drivers of lifetime costs for 
people with schizophrenia. Lurasidone is predicted to have the lowest rates of these adverse 
events, and so the lowest costs amongst patients initiating acute treatment in seven European 
countries compared to nine other antipsychotics. Future research should investigate the 
individual costs of relapse management, including differences in the costs and proportions 
of hospitalizations.
Keywords: cost analysis, side-effects, Europe, acute treatment, maintenance treatment
Plain Language Summary
People with schizophrenia can be treated with antipsychotics. These are often effective at 
controlling the symptoms of schizophrenia but can also result in a number of side effects. 
These include diabetes, weight gain, and conditions that affect the heart or blood vessels 
(cardiovascular diseases). The rates of these side effects vary with choice of antipsychotic, 
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and the costs of treating these side effects is also different in 
different countries. The aim of our research was to identify the 
full costs of using antipsychotics to treat people with schizophre-
nia. The results of this research will help to guide the choice of 
antipsychotic for schizophrenia treatment.
We considered ten antipsychotics and looked at the costs in 
seven different European countries: Italy, Hungary, France, 
Slovenia, Spain, Sweden and the UK. We included the costs of 
the antipsychotic treatment, the costs of treating side effects, and 
the costs of managing schizophrenia (such as when people 
relapse). We searched for published evidence for both antipsy-
chotics (how well they work and how many side effects people 
have) and country-specific costs. We used a mathematical model 
to bring all this evidence together and estimate likely lifetime 
costs.
We found that, of the ten antipsychotics, Lurasidone and 
Ziprasidone had the lowest lifetime costs in all seven countries. 
This was mainly because their use led to lower rates of diabetes, 
cardiovascular diseases, and weight gain.
Introduction
Treating cardiovascular and metabolic (cardiometabolic) 
diseases can result in large costs to healthcare systems. 
In Europe, the annual cost of cardiovascular diseases in the 
general population was estimated to be €111 billion in 
2015, whilst the global cost of diabetes is projected to 
reach $490 billion by 2030.1,2 There is an elevated risk 
of cardiometabolic disease amongst patients with schizo-
phrenia; compared with the general population they are 
twice as likely to have diabetes,3 and twice as likely to be 
diagnosed and die with CVD,4 contributing to a reduction 
in life expectancy of 15 years.5 The risk factors for cardi-
ometabolic disease are affected by choice of antipsychotic 
treatment.6
As schizophrenia is a life-long disorder it is important to 
consider the lifetime costs and adverse health effects asso-
ciated with the choice of antipsychotic. This is a particular 
concern for second-generation antipsychotics which have 
similar efficacy for improving the acute symptoms of schi-
zophrenia but differ in their side effect profiles. Clinical 
guidelines recommend that the choice of antipsychotic is 
driven primarily by rates of side effect, of which weight 
gain and associated cardiometabolic diseases play a promi-
nent role.7 The treatment of side effects is not the only driver 
of lifetime costs. Relapses and treatment discontinuation 
will also vary by antipsychotic and contribute to overall 
costs.8,9 Overall costs will vary by country due to differences 
in healthcare systems, treatment pathways, and the distribu-
tions of cardiometabolic risk factors. Existing studies have 
sought to quantify the lifetime costs for people with 
schizophrenia.10–16 However, these studies only consider 
selected side effects for a small number of antipsychotics 
and are restricted to a single country.
The aim of this study was to estimate, for several 
European countries and several second-generation antipsy-
chotics, the total lifetime costs associated with the man-
agement of schizophrenia and the treatment of side effects 
including cardiometabolic diseases. To support this 
research, systematic searches of the literature were con-
ducted to identify both country-specific costs and antipsy-
chotic-specific effectiveness and side effect data. To 
predict the incidence of long-term cardiometabolic dis-
eases, risk models were used that are adjusted to be spe-
cific to a population with schizophrenia.
Methods
An economic model was developed to synthesise evi-
dence on the effectiveness of specific second-generation 
antipsychotics, country-specific costs (including costs of 
antipsychotics and treating cardiometabolic diseases), 
country-specific risk factors for cardiometabolic diseases, 
and risk models to estimate long-term outcomes. Ten 
antipsychotics were included: aripiprazole, brexpipra-
zole, cariprazine, lumateperone, lurasidone, olanzapine, 
paliperidone, quetiapine, risperidone, and ziprasidone. To 
limit the number of antipsychotics to a feasible amount, 
only second- and third-generation atypical antipsychotics 
that are available and have the highest market shares on 
average in Europe were considered. Seven European 
countries were included: France, Hungary, Italy, 
Slovenia, Spain, Sweden, and the UK. The choice of 
country was based on the availability of country-specific 
cost data. Two adult populations; initiating either acute or 
maintenance antipsychotic treatment were modelled and 
followed-up for 50 years (assumed to represent a lifetime 
horizon) to capture all relevant differences in outcomes 
and costs.
Review of Clinical Evidence
A literature review was undertaken to identify existing 
systematic reviews, meta-analyses, network meta-analyses 
(NMAs) and indirect treatment comparisons of rando-
mised controlled trials (RCTs). MEDLINE, Embase and 
the Cochrane Database of Systematic Reviews were 
searched in February 2020 based on the following combi-
nations of search concepts: schizophrenia AND (antipsy-
chotics OR 10 individual drugs) AND relevant outcome 
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terms AND systematic review or meta-analysis or NMAs 
or indirect comparison. A full set of synonyms was used 
for each concept; the full MEDLINE search terms are 
provided in Appendix 1, with further details, including 
the inclusion criteria, provided in Appendix 2. The search 
covered publications from the year 2000 onwards. The 
most up-to-date analyses covering relevant interventions 
and reporting relevant outcomes were selected for full data 
extraction.
The evidence review considered a long list of 33 pre- 
defined outcomes including cardiometabolic risk factors 
and outcomes as well as effectiveness outcomes; the full 
list is replicated in Appendix 2. Consistent with existing 
economic evaluations, it was assumed that antipsychotics 
had similar efficacy for change in symptoms, so evidence 
on these was not collected.17–21 Both short-term 
outcomes (up to 13 weeks, typically six weeks) and 
longer-term outcomes (available up to three years) were 
considered. The majority of the data was obtained from 
NMAs of RCTs of multiple antipsychotics (Table 1). 
There remained some evidence gaps after conducting 
the review of NMAs and meta-analyses. Hence, addi-
tional searches in PubMed and ClinicalTrials.gov were 
undertaken to identify individual RCTs. Systematic 
reviews were also checked for relevant trials. Individual 
trials were sought and identified for lumateperone (short- 
term outcomes) and cariprazine and brexpiprazole (long- 
term outcomes).22–25 No long-term outcomes were 
identified for lumateperone, hence for the model these 
outcomes were assumed to be the average of the other 
antipsychotics. A total of 12 outcomes were used from 
the review of clinical evidence including change in lipids 
and fasting plasma glucose, weight gain, treatment dis-
continuation and relapse rates; the values and data 
sources for each are provided in Table 1. An overview 
of the key studies identified for the relevant outcomes is 
provided in Appendix 2. Blood pressure was identified as 
being a key outcome for which there was a lack of 
evidence. Targeted literature reviews, and contacting 
authors of key NMAs, did not identify any evidence 
that blood pressure outcomes differed by antipsychotic, 
hence it was assumed that there was no treatment effect. 
No evidence for specific antipsychotics was identified for 
rates of type 2 diabetes, stroke, myocardial infarction and 
metabolic syndrome. Risk models were used to estimate 
the first three outcomes as described subsequently (and in 
more detail in Appendix 3), whilst Appendix 4 provides 
details on how rates of metabolic syndrome were 
estimated.
Risk Models
Risk models were used to link short-term changes in 
weight, cholesterol (total and high-density lipoprotein) 
and fasting plasma glucose to the probability of develop-
ing type 2 diabetes, stroke and myocardial infarction. For 
this analysis, QDiabetes was used to estimate the risk of 
developing type 2 diabetes, whilst QRisk was used to 
estimate the risk of developing a cardiovascular event 
(stroke or myocardial infarction).26,27 In contrast to other 
risk models,28,29 both of these risk models have been 
independently validated, and were derived on a European 
(UK) cohort whilst also including adjustment for both 
antipsychotic use and having schizophrenia/severe mental 
illness.
Where possible the risk models were populated using 
mean country-specific values as inputs. Details on all the 
inputs used, and their sources, are provided in Appendix 3.
Evidence on Costs
A systematic search was performed to identify country- 
specific costs relating to the management of schizophrenia 
and the treatment of side effects. MEDLINE was searched 
in February 2020, full details of the search terms used are 
provided in Appendix 1. As with the searches for clinical 
effectiveness, the cost search originally considered the 
long list of 33 pre-defined outcomes. Country-specific 
costs used in the analysis are provided in Table 2. All 
costs were inflated to 2018 costs. For comparability across 
countries, Table 2 reports costs in a common currency (US 
$), whereas for the analysis country-specific currencies are 
used; when country-specific costs were not available pur-
chasing power parities were used (see Appendix 4 for 
more details). The cost perspective was direct medical 
costs. An overview is provided here; further details 
(including full references) are provided in Appendix 4, 
which also provides details on the search process.
In general, preference was given to the most recent 
studies. Clinically relevant weight gain was defined as an 
increase of at least 7% from baseline weight. The majority 
of studies costed cardiometabolic outcomes based on costs 
from the general population, this approach was used here. 
Most studies provided an overall cost of treating diabetes 
and its complications. This will lead to double-counting as 
some of the complication costs will be for cardiovascular 
diseases, hence these costs were multiplied by 0.78.30 The 
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Table 1 Clinical Effectiveness Evidence: Short-Term and Long-Term Outcomes








































Lurasidone 0.88 0.32 0.02 −0.03 0 −0.29 7.04 −2.21 0.30 0.97 −0.88 −0.09
Aripiprazole 0.8 0.48 0.04 0.06 0.02 0.13 −7.1 −0.43 0.64 1.34 −0.60 0.02
Brexpiprazole 0.89 0.7 0.05 0.05 −0.01 0.04 0.95 −1.46 0.35 0.45 1.90 0.21
Cariprazine 0.93 0.73 0.02 −0.09 0.01 0.26 −3.19 −1.45 0.52 0.91 0.19 0.07
Olanzapine 0.69 2.78 −0.01 0.4 0.46 0.2 4.47 4.29 0.24 0.58 3.05 0.22
Paliperidone 0.7 1.49 0.01 0.06 0.04 0.08 48.51 1.21 0.26 1.40 2.12 0.12
Quetiapine 0.85 1.94 0.01 0.31 0.32 0.09 −1.17 3.43 0.38 0.69 1.74 0.09
Risperidone 0.82 1.44 0.01 0.06 0.04 0.08 37.98 4.77 0.33 1.02 2.12 0.05
Ziprasidone 0.9 −0.16 0.05 −0.04 0.02 0.05 2.75 9.7 0.28 0.77 −1.35 −0.09
Lumateperone 0.67 0.66 0.02 −0.07 −0.06 −0.08 −1.29 1.98 0.37 0.90 0.92 0.07















Notes: All comparisons are against placebo; Data are mean differences, unless otherwise indicated; *Short-term evidence for lumateperone is a weighted average of data from Lieberman 2015 and Correll 2020 (RCTs);22,23 Long-term 
evidence for brexpiprazole and cariprazine are from Fleischhacker 2017 and Durgam 2016 respectively (RCTs);24,25 Long-term evidence for lumateperone is not available, so average values for the other antipsychotics were used. Both 
long-term relative risks for lurasidone were from Kishimoto 2019 (meta-analysis of RCTs);43 See Appendix 4 for details on evidence sources for long-term weight gain. 
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costs of cardiovascular disease included country-specific 
costs of stroke and myocardial infarction. For both out-
comes separate costs were obtained for fatal events as well 
as for the first and subsequent years for non-fatal events. 
The overall cardiovascular costs were a weighted average 
of stroke and myocardial infarction costs, assuming that 
myocardial infarction events contributed to 61% of fatal 
and 47% of non-fatal cardiovascular events. These propor-
tions were based on those observed in a large cohort of 
individuals with serious mental illness (of those with a 
recorded diagnosis, 39% had schizophrenia and 30% had 
bipolar disorder).28 Due to a lack of country-specific costs 
for treating metabolic syndrome, costs from a Swedish 
study were used for all countries.21 The development of 
hyperprolactinaemia was costed as requiring a GP visit 
every three months and one endocrinologist visit a year. 
Management of QT prolongation was assumed to require 
one additional visit each to a psychiatrist and a cardiolo-
gist every six months.
For the costs of disease management (relapse and 
stable disease), the costs of antipsychotic treatment were 
excluded to avoid double-counting. The costs of relapse 
were a weighted average of the costs of relapses requiring 
and not requiring hospitalisations, using country-specific 
weights where available. Treatment switching was 
assumed to require three psychiatrist visits.18
Country-specific costs of the public prices paid for 
antipsychotics were provided by Angelini (an Italian 
group present in Pharmaceuticals and Mass-Market inter-
nationally, with core work in rare diseases, mental health, 
inflammation and consumer health) and are confidential. 
This evidence did not include the cost of lumateperone, so 
a monthly cost of $1,320 was assumed based on a press 
release.31
Model Structure and Methods
A cohort Markov model was developed in Microsoft Excel 
to synthesise data on clinical effectiveness, costs, and risk 
models.32 Costs were discounted at 3.5% per year. As both 
risk models provided separate estimates for males and 
females, all analyses were performed separately by sex. 
Overall results were obtained as a country-specific 
weighted average of the sex-specific results. Two popula-
tions were considered: patients initiating acute treatment 
for schizophrenia, and patients initiating maintenance 
treatment. For consistency with the main evidence sources, 
the patient population was defined as adults with schizo-
phrenia or a related disorder (such as schizoaffective or 
schizophreniform).6,9
For schizophrenia both acute and longer-term out-
comes are important. To align with the clinical evidence, 
the model included an initial six-week acute treatment 
period, followed by a longer-term period of maintenance 
treatment and remission, with a cycle length of one year. 
Patients initiating acute treatment began in the acute 
phase, and moved into the longer-term phase following 
successful treatment. Treatment effects for those initiating 
maintenance treatment began on entering the long-term 
phase. The model had nine health states, as shown in 
Figure 1. In addition, the treatment outcomes of relapse, 
discontinuation and remission were also modelled, as were 
changes in risk factors over time. Patients who discontin-
ued treatment or experienced a relapse received subse-
quent treatment with a different antipsychotic. It was 
Table 2 Country-Specific Annual per Patient Costs (US $)
France Hungary Italy Slovenia Spain Sweden UK
Weight gain 624 47 229 229 229 463 208
Diabetes 6,677 5,046 3,478 1,242 2,062 3,417 6,553
Fatal CVD event 8,142 4,137 5,178 4,137 10,575 8,175 5,158
CVD event Year 1 23,572 3,006 7,310 11,685 13,557 6,325 4,093
CVD event Years 2+ 3,272 1,170 6,405 496 11,060 2,207 1,702
Metabolic syndrome 970 970 970 970 970 970 970
Hyperprolactinaemia 172 83 197 83 360 860 404
QT prolongation 441 129 493 129 477 1,461 832
Stable disease 1,508 612 341 1,089 4,949 10,826 2,497
Relapse 13,707 3,960 1,746 13,352 9,866 16,687 10,605
Treatment switching 330 97 370 97 358 1,096 624
Abbreviation: CVD, cardiovascular disease; includes country-specific proportions of stroke and myocardial infarction.
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assumed that subsequent treatment represented a blended 
average of the available antipsychotics, and so the average 
effectiveness (and costs) for these was used. Due to its 
high cost, lumateperone was not included when calculating 
the blended cost. Patients were assumed to be in remis-
sion, and so not require treatment with antipsychotics, 
after experiencing two years of maintenance treatment 
without either a relapse or treatment discontinuation.7 
Hence changes in long-term changes in weight gain and 
fasting plasma glucose levels could only occur for up to 
two years. For the cardiometabolic health states in Figure 
1, costs were based on the proportion of the cohort in each 
health state at each time cycle. The remaining costs (for 
weight gain, hyperprolactinaemia, QT prolongation, treat-
ment discontinuation and relapses) were based on the 
proportion of the cohort experiencing these events per 
time cycle (for more details, see Appendix 4).
Country-specific age and sex life tables were used to 
model the probability of non-cardiovascular mortality. To 
account for the increased probability of death amongst 
people with schizophrenia, standardised mortality ratios 
were applied. Country-specific values were identified for 
Hungary (2.4 for both sexes),33 Sweden (2.8 men, 2.4 
women)10 and the UK (2.9 men, 2.8 women).34 For the 
remaining countries values from a European meta-analysis 
were used: 3.0 for men and 2.4 for women.35
To assess uncertainty, both probabilistic and determi-
nistic sensitivity analyses were undertaken. For the prob-
abilistic sensitivity analysis 1,000 iterations were 
undertaken; proportions were modelled with a beta distri-
bution, a Dirichlet distribution was used for multinomial 
data (ethnicity and smoking status), costs were modelled 
with a gamma distribution (drug costs were assumed 
known and so fixed), with the remaining parameters mod-
elled via a Normal distribution. The following determinis-
tic sensitivity analyses were conducted:
1. For the treatment effect on weight gain during the 
acute period use results from the network meta- 
analysis of Pillinger and colleagues.6
2. For the treatment effect on relapses during the main-
tenance period use results from the network meta- 
analysis of Millier and colleagues where available 
(as no data were available for paliperidone it was 
assumed to have the same effectiveness as 
olanzapine).8
3. Alternative estimates for the cost of relapse and 
stable disease from the European SOHO study.36
4. Alternative weight gain costs for France,37 Spain,20 
Sweden,10 and the UK18 (in the absence of evidence, 
costs for Hungary and Slovenia were both derived 
from the UK costs, whilst costs for Italy were 
derived from the Spanish costs).
5. Use the same starting age for all countries, based on 
the meta-analysis of Huhn and colleagues.9
6. Use the same percent of females for all countries, 
based on the meta-analysis of Huhn and colleagues.9
7. Use starting values for metabolic parameters from 
an alternative study.38
8. Reducing all-cause mortality rates by 37% to 
account for having cardiovascular deaths as a sepa-
rate heath state.39
Results
An overview of the lifetime costs for the cohort starting 
with acute treatment is provided in Table 3, whilst results 
for the cohort starting with maintenance treatment are 
provided in Table 4. For both tables results are ordered 
Figure 1 Model schematic (patient health states). 
Abbreviation: CVD, cardiovascular disease.
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by total costs for the UK and are reported using country- 
specific currencies. A full breakdown of costs is provided 
in Appendix 5 Tables 6 and 7.
Lurasidone was associated with the lowest lifetime 
costs amongst patients initiating acute treatment compared 
to all other atypical antipsychotics considered. This result 
was similarly observed in all 7 countries considered. The 
second lowest costs were for ziprasidone. The main dri-
vers of cost differences were rates of diabetes and cardio-
vascular diseases, which were lowest for lurasidone, 
followed by ziprasidone then lumateperone. On average, 
cardiometabolic outcomes accounted for approximately 
two thirds of the total lifetime costs, although it varied 
by country being the highest in Italy and lowest in 
Slovenia. Costs for managing weight gain were lowest 
for ziprasidone and lurasidone. Total costs were very simi-
lar for aripiprazole, brexpiprazole and risperidone and 
these drugs always have the lowest overall costs after 
lurasidone and ziprasidone. The drugs resulting in the 
highest overall cost were olanzapine and lumateperone 
for all of the countries considered. For lumateperone, the 
main cost driver was the cost of the drug which contrib-
uted to between 21% and 46% of total costs. For the other 
antipsychotics, drug costs varied from 1% of the total cost 
(olanzapine in France and Spain) to 10% (lurasidone in 
Hungary). If lumateperone cost the same as lurasidone, it 
would have the third lowest overall cost for all countries 
(behind lurasidone and ziprasidone).
For patients initiating maintenance treatment lurasidone 
and ziprasidone were associated with the lowest lifetime 
costs, in all countries considered. The highest costs were 
again generally observed for olanzapine and lumateperone. 
Reducing the cost for lumateperone to be the same as for 
lurasidone led to its total cost being between the sixth lowest 
(Sweden) and third lowest (Spain). More variation in the 
ranking of the remaining antipsychotics was observed for 
the maintenance population compared with the acute popu-
lation. For example, aripiprazole had the third lowest costs 
for four countries (France, Italy, Hungary, UK), but the 
second highest costs for Slovenia, and the fourth and fifth 
highest costs for Spain and Slovenia, respectively. The rela-
tive contribution of cardiometabolic outcomes to overall 
Table 3 Lifetime Costs, Patients Initiating Acute Treatment (Country-Specific Currencies)
France (€) Hungary (HUF) Italy (€) Slovenia (€) Spain (€) Sweden (SEK) UK (£)
Lurasidone 60,504 4,020,850 39,828 24,459 67,028 926,893 42,262
Ziprasidone 67,714 4,695,375 46,217 24,526 69,351 931,621 48,135
Aripiprazole 82,391 5,863,345 54,843 29,665 76,136 1,076,633 58,924
Risperidone 84,163 5,862,550 58,202 27,919 75,304 1,070,426 59,264
Brexpiprazole 85,697 6,221,213 59,545 27,919 75,073 1,071,224 61,399
Quetiapine 88,911 6,385,937 61,545 29,710 78,557 1,105,502 62,458
Paliperidone 86,969 6,279,349 61,088 28,621 76,374 1,086,452 63,624
Cariprazine 89,945 6,760,236 61,538 30,429 77,669 1,130,224 66,047
Lumateperone 94,115 8,869,189 68,497 41,789 88,634 1,229,085 70,374
Olanzapine 108,267 8,424,887 78,386 32,193 85,071 1,248,390 77,727
Table 4 Lifetime Costs, Patients Initiating Maintenance Treatment (Country-Specific Currencies)
France (€) Hungary (HUF) Italy (€) Slovenia (€) Spain (€) Sweden (SEK) UK (£)
Ziprasidone 69,950 4,909,048 48,538 24,932 70,486 935,980 50,061
Lurasidone 71,960 5,109,301 49,590 26,055 71,306 989,858 52,063
Aripiprazole 82,795 5,839,141 55,156 30,158 76,456 1,083,370 59,733
Risperidone 84,367 5,928,102 58,504 28,198 75,427 1,070,048 60,289
Cariprazine 83,487 6,011,674 56,611 29,589 76,035 1,079,753 60,670
Quetiapine 85,504 6,059,230 59,188 28,602 76,000 1,075,033 61,189
Paliperidone 86,969 6,279,349 61,088 28,621 76,374 1,086,452 63,624
Brexpiprazole 90,730 6,652,409 63,910 28,876 77,331 1,107,355 65,858
Olanzapine 94,090 6,871,632 67,536 28,501 77,635 1,127,000 67,802
Lumateperone 93,142 7,837,639 66,641 36,066 83,910 1,180,117 69,145
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costs was almost identical amongst those initiating mainte-
nance and acute treatments.
Results from probabilistic sensitivity analyses are demon-
strated in Figure 2, which demonstrates the distribution of 
lifetime costs, and Appendix 5 Table 7 which provides the 
probability that each treatment has the lowest overall costs, 
per country. Figure 2 demonstrates substantial variability 
across iterations. For each country lurasidone always had 
the highest probability of having the lowest overall costs. 
For Slovenia and Sweden, the probability was 35.4% and 
38.4%, respectively. For the remaining five countries lurasi-
done had the lowest overall costs in the majority of the 
iterations (range: 54.8% in Spain to 77.8% in Italy). 
Ziprasidone always had the second highest probability 
(range: 19.2% in Italy to 77.8% in Sweden); no other treat-
ment had a probability above 8.6% (risperidone in Slovenia).
Results for the seven deterministic sensitivity analyses 
are provided in Appendix 5 Table 8. In general results for 
these were very similar to the main analysis, with lurasidone 
and ziprasidone being the two drugs with the lowest lifetime 
costs in the majority of analysis, whilst olanzapine and 
lumateperone generally had the two highest costs. The 
main exception was for the second sensitivity analysis (alter-
native values for long-term relapse), for which brexpiprazole 
had the lowest lifetime costs for Slovenia (lurasidone had the 
lowest costs for all other countries), and the second lowest 
costs for Spain and Sweden.
Discussion
Lurasidone and ziprasidone were associated with the 
lowest total lifetime costs when initiated as acute or 
maintenance treatments for all seven countries consid-
ered. This was primarily due to the avoidance of dia-
betes and cardiovascular events, although costs of 
weight gain were also lowest for these two drugs. The 
rankings of the remaining antipsychotics varied by 
country, emphasising the importance of considering 
country-specific costs.
Figure 2 Distribution of lifetime costs (acute population).
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Existing evaluations of lifetime costs amongst people 
with schizophrenia only considered a small number of 
antipsychotics or a limited range of cardiometabolic out-
comes. This limits the comparability of their results to this 
study. The most comprehensive previous evaluation was 
that conducted for the UK NICE clinical guidelines on the 
treatment and management of schizophrenia in adults.18 
This evaluation included four of the ten antipsychotics 
considered here (aripiprazole, olanzapine, paliperidone, 
risperidone), as well as the main cardiometabolic out-
comes (diabetes, stroke and myocardial infarction). It 
found that olanzapine and paliperidone (which had the 
lowest relapse rates) had the lowest lifetime costs but did 
not provide a cost breakdown. The results are in contrast 
with this analysis, for which olanzapine and paliperidone 
still had the lowest relapse rates (0.24 and 0.26 respec-
tively, compared to 0.30 for lurasidone) but also had some 
of the highest costs in the UK. These differences may be 
due to the estimated cost of relapse, which were about four 
times greater in the NICE evaluation. As discussed in 
Appendix 4, the relapse costs used by NICE are much 
larger than any of the other relapse costs identified, and so 
may lack face validity. Two other studies were identified 
which evaluated the long-term impact of cardiometabolic 
outcomes, both of which included aripiprazole.21,29 In a 
Swedish study the comparator was olanzapine, in a UK 
study the comparator was standard of care. Both studies 
found that the lower rates of cardiometabolic outcomes 
with aripiprazole led to lower lifetime costs, consistent 
with the results of this analysis.
To the authors’ knowledge, this is the first study to com-
prehensively consider multi-country costs for a large number 
of second-generation antipsychotics. The large number of 
treatments and outcomes considered is a particular strength 
of this work. The identification of effectiveness data and costs 
were also based on systematic searches of the literature, sup-
plemented by targeted literature searches, to ensure that the 
most relevant evidence was identified. The use of an economic 
model with validated risk equations allowed for the synthesis 
of evidence, with extrapolation of longer-term outcomes. 
Another strength of this study is that, where possible, effec-
tiveness data were obtained from NMAs of multiple antipsy-
chotics, representing high level evidence. Of the identified 
studies that estimated the costs of any cardiometabolic out-
comes, only two included an NMA.18,40
There are limitations with this project. High quality 
evidence about the short-term impact on triglycerides was 
available,6 but it was not possible to link this to costs or to 
differences in long-term outcomes. Of the drugs considered, 
lurasidone and brexpiprazole were particularly effective at 
controlling triglyceride levels, so the lifetime costs for these 
treatments may be under-estimated. There were also some 
key evidence gaps; including evidence on the long-term 
effectiveness of lumateperone. Further, as the NMAs did 
not always include all ten antipsychotics, they were supple-
mented by trial evidence. This may lead to inconsistent 
estimates, so future research should seek to incorporate this 
evidence within NMAs. Whilst treatment-specific differ-
ences in the rates of relapse were modelled, treatment-spe-
cific differences in the proportions of relapses requiring 
hospitalisation were not modelled due to an absence of 
evidence. Future research should investigate the proportions 
of relapses that lead to hospitalisations, by antipsychotic. 
When possible, inputs for risk models were for a schizo-
phrenia population, but where this data was lacking it was 
obtained from the general population. This will affect the 
absolute accuracy of country-specific estimates, but not the 
relative outcomes by antipsychotic. In addition, the costs of 
treating neurological side effects, such as extrapyramidal 
symptoms and tardive dyskinesia, were not included. 
Relative to the costs of chronic cardiometabolic disease, 
including the costs of treating acute neurological side effects 
is not anticipated to greatly influence the findings of this 
study. The use of standardised mortality ratios applied to 
life-table data in addition to the explicit modelling of CVD 
deaths may lead to some double-counting of deaths. 
However, this was explored in a sensitivity analyses, which 
suggests that results are robust to any double-counting. As 
with any analysis which uses evidence from the published 
literature, there is the possibility of publication bias.
Clinical guidelines for antipsychotic treatment in schi-
zophrenia emphasise the importance of considering the 
adverse event profile of drugs.7 This study has estimated 
the rates of major cardiometabolic outcomes for ten anti-
psychotics, as well as quantifying the contribution of these 
adverse events to lifetime treatment costs for seven 
European countries. The results indicate that the develop-
ment of diabetes and cardiovascular events are the primary 
cost drivers, and so the risk of developing these should be 
a key consideration in the choice of antipsychotic.
To conclude, when making decisions about the choice 
of antipsychotic for treating schizophrenia, it is important 
to consider lifetime outcomes. Cardiometabolic outcomes 
are a key long-term outcome which typically have a bigger 
impact on total costs than other schizophrenia treatment 
costs, such as managing relapses. Amongst the ten 
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antipsychotics considered, lurasidone and ziprasidone had 
the lowest rates of cardiometabolic outcomes and lowest 
lifetime costs in seven European countries.
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